Exact Mass: 383.1037

Exact Mass Matches: 383.1037

Found 72 metabolites which its exact mass value is equals to given mass value 383.1037, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Acutumidine

Dauricumidine

C18H22ClNO6 (383.1136)


   

Lilaline

3,5,7,4-Tetrahydroxy-8- (3-methyl-2-oxo-5-pyrrolidinyl) flavone

C20H17NO7 (383.1005)


A tetrahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 7 and 4 and a 4-methyl-5-oxopyrrolidin-2-yl group at position 8.

   

Tebipenem

Tebipenem

C16H21N3O4S2 (383.0973)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

   

Atropine methobromide

Hyoscyamine methylbromide

C18H26BrNO3 (383.1096)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics Atropine methyl bromide, a muscarinic receptor (mAChR) antagonist, is a quaternary ammonium salt of atropine and a mydriatic for dilation of the pupil during ophthalmic examination. It is introduced for relieving pyloric spasm in infants for its highly polar nature. It penetrates less readily into the central nervous system than atropine[1][2].

   

N6-succinyladenosine

(2S)-2-({9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}amino)butanedioic acid

C14H17N5O8 (383.1077)


Succinyladenosine (SAdo) is one of the dephosphorylated enzyme substrate that accumulates in body fluids of patients with adenylosuccinate lyase (ADSL) deficiency, the other being 5-amino-4-imidazole-N-succinocarboxamide riboside (SAICAr). ADSL is an inherited metabolic disease characterized by various degrees of psychomotor retardation (PMID 15902552). The severity of the clinical presentation correlates with a low S-Ado/SAICAr ratio in body fluids (PMID: 15571235). Normally Succinyladenosine is not found in blood or CSF but may be detected in trace amounts in urine (OMIM 103050). Succinyladenosine is also found to be associated with fumarase deficiency, another inborn error of metabolism. Succinyladenosine (SAdo) is one of the dephosphorylated enzyme substrate that accumulates in body fluids of patients with adenylosuccinate lyase (ADSL) deficiency, the other being 5-amino-4-imidazole-N-succinocarboxamide riboside (SAICAr). ADSL is an inherited metabolic disease characterized by various degrees of psychomotor retardation. (PMID 15902552)

   

N6-Succinyl Adenosine

2-({9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}amino)butanedioic acid

C14H17N5O8 (383.1077)


N6-Succinyl Adenosine (Succinyl-AMP) is a nucleotide derivative that possesses a unique chemical structure and plays significant roles in various biological processes. Its chemical structure consists of adenosine, a nucleoside composed of the nitrogenous base adenine and ribose sugar, with an additional succinyl group attached to the N6 position of the adenine base. This succinyl group is derived from succinic acid, a four-carbon dicarboxylic acid. The presence of the succinyl group at the N6 position of adenine alters the physicochemical properties of adenosine, influencing its interactions with enzymes and other molecules in the cell. This modification is biologically relevant, as N6-succinyl adenosine is involved in several metabolic pathways and regulatory mechanisms. Biologically, N6-succinyl adenosine is known for its role in the regulation of gene expression. It can serve as a substrate for the formation of N6-threonylcarbamoyladenosine (t6A), a key modification found in the wobble position of certain tRNAs. This modification is critical for the efficiency of translation initiation and the accuracy of decoding the genetic code. Moreover, N6-succinyl adenosine is involved in the transsulfuration pathway, a metabolic route that interconverts sulfur-containing amino acids. It acts as a precursor for the synthesis of cysteine, an essential amino acid that plays a vital role in protein structure and function, as well as in the synthesis of glutathione, a major antioxidant in the cell. Additionally, N6-succinyl adenosine has been implicated in the process of protein succinylation, a novel post-translational modification where the succinyl group is transferred to lysine residues of proteins. This modification can affect protein function, stability, and cellular signaling pathways. 2-({9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}amino)butanedioic acid belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Based on a literature review very few articles have been published on 2-({9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}amino)butanedioic acid. This compound has been identified in human blood as reported by (PMID: 31557052 ). N6-succinyl adenosine is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N6-Succinyl Adenosine is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.

   

Tebipenem

(4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C16H21N3O4S2 (383.0973)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

   
   
   

MCULE-2715920117

MCULE-2715920117

C19H17N3O6 (383.1117)


   

N-(2,3-Dihydro-1H-indol-1-ylcarbothioyl)-5-(2-phenylethynyl)nicotinamide

N-(2,3-Dihydro-1H-indol-1-ylcarbothioyl)-5-(2-phenylethynyl)nicotinamide

C23H17N3OS (383.1092)


   

MCULE-1441994257

MCULE-1441994257

C19H17N3O6 (383.1117)


   

SCHEMBL3227802

SCHEMBL3227802

C20H17NO7 (383.1005)


   

1-acetyl-12-glutamyl-beta-carboline-3-carboxylate|dichotomine H|N-[(1-acetyl-9H-beta-carbolin-3-yl)carbonyl]-L-glutamic acid|tunicoidine B

1-acetyl-12-glutamyl-beta-carboline-3-carboxylate|dichotomine H|N-[(1-acetyl-9H-beta-carbolin-3-yl)carbonyl]-L-glutamic acid|tunicoidine B

C19H17N3O6 (383.1117)


   
   

13a-hydroxy-9,10-dimethoxy-2,3-(methylenedioxy)-8,13-dioxo-5,6,13,13a-tetrahydro-8H-dibenzoquinolizine|13a-hydroxy-9,10-dimethoxy-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline-8,13-dione|8,13-dioxo-14-hydroxy-2,3-methylenedioxy-9,10-dimethoxytetrahydroprotoberberine|8,13-Dioxo-14-hydroxycanadin|prechilenine

13a-hydroxy-9,10-dimethoxy-2,3-(methylenedioxy)-8,13-dioxo-5,6,13,13a-tetrahydro-8H-dibenzoquinolizine|13a-hydroxy-9,10-dimethoxy-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline-8,13-dione|8,13-dioxo-14-hydroxy-2,3-methylenedioxy-9,10-dimethoxytetrahydroprotoberberine|8,13-Dioxo-14-hydroxycanadin|prechilenine

C20H17NO7 (383.1005)


   
   
   

2-[[1-(4-nitrobenzoyl)pyrrolidine-2-carbonyl]amino]benzoic acid

2-[[1-(4-nitrobenzoyl)pyrrolidine-2-carbonyl]amino]benzoic acid

C19H17N3O6 (383.1117)


   

N6-Succinyladenosine; LC-tDDA; CE10

N6-Succinyladenosine; LC-tDDA; CE10

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; LC-tDDA; CE20

N6-Succinyladenosine; LC-tDDA; CE20

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; LC-tDDA; CE30

N6-Succinyladenosine; LC-tDDA; CE30

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; LC-tDDA; CE40

N6-Succinyladenosine; LC-tDDA; CE40

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE0; CorrDec

N6-Succinyladenosine; AIF; CE0; CorrDec

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE10; CorrDec

N6-Succinyladenosine; AIF; CE10; CorrDec

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE30; CorrDec

N6-Succinyladenosine; AIF; CE30; CorrDec

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE0; MS2Dec

N6-Succinyladenosine; AIF; CE0; MS2Dec

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE10; MS2Dec

N6-Succinyladenosine; AIF; CE10; MS2Dec

C14H17N5O8 (383.1077)


   

N6-Succinyladenosine; AIF; CE30; MS2Dec

N6-Succinyladenosine; AIF; CE30; MS2Dec

C14H17N5O8 (383.1077)


   
   
   

Fenoterol sulfate

Fenoterol sulfate

C17H21NO7S (383.1039)


   

Succinoadenosine

Succinoadenosine

C14H17N5O8 (383.1077)


   

Ala-Trp-OH

(S)-3-(1H-indol-3-yl)-2-(3-methoxy-4-nitrobenzamido)propanoic acid

C19H17N3O6 (383.1117)


   

Trp-Gly-OH

2-(3-(2-(1H-indol-3-yl)ethoxy)-4-nitrobenzamido)acetic acid

C19H17N3O6 (383.1117)


   

2-{[1-(4-Nitrobenzoyl)prolyl]amino}benzoic acid

2-{[1-(4-Nitrobenzoyl)prolyl]amino}benzoic acid

C19H17N3O6 (383.1117)


   

morphine sulfate

morphine sulfate

C17H21NO7S (383.1039)


   
   

tert-Butyl 4-(4-bromo-3,5-dimethylphenoxy)piperidine-1-carboxylate

tert-Butyl 4-(4-bromo-3,5-dimethylphenoxy)piperidine-1-carboxylate

C18H26BrNO3 (383.1096)


   

1,3,4,6-TETRA-O-ACETYL-2-AMINO-2-DESOXY-BETA-D-GLUCOPYRANOSE HYDROCHLORIDE

1,3,4,6-TETRA-O-ACETYL-2-AMINO-2-DESOXY-BETA-D-GLUCOPYRANOSE HYDROCHLORIDE

C14H22ClNO9 (383.0983)


   

b-D-Glucopyranose,2-amino-2-deoxy-, 1,3,4,6-tetraacetate, hydrochloride (1:1)

b-D-Glucopyranose,2-amino-2-deoxy-, 1,3,4,6-tetraacetate, hydrochloride (1:1)

C14H22ClNO9 (383.0983)


   

2-(4-chlorophenoxy)-N-[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-yl]acetamide

2-(4-chlorophenoxy)-N-[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-yl]acetamide

C20H18ClN3O3 (383.1037)


   

1-(chloroacetyl)-3-(1H-indol-3-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-4-ol

1-(chloroacetyl)-3-(1H-indol-3-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-4-ol

C20H18ClN3O3 (383.1037)


   

(2S)-2-[[9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid

(2S)-2-[[9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid

C14H17N5O8 (383.1077)


   

N-[(2-naphthalen-2-yloxypropanoylamino)carbamothioyl]furan-2-carboxamide

N-[(2-naphthalen-2-yloxypropanoylamino)carbamothioyl]furan-2-carboxamide

C19H17N3O4S (383.094)


   

6-Chloro-4-phenyl-3-(1-phenyl-5-tetrazolyl)quinoline

6-Chloro-4-phenyl-3-(1-phenyl-5-tetrazolyl)quinoline

C22H14ClN5 (383.0938)


   

2-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-N-(1,1-dioxothiolan-3-yl)-N-ethylacetamide

2-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-N-(1,1-dioxothiolan-3-yl)-N-ethylacetamide

C15H21N5O3S2 (383.1086)


   

5-(1-Phenyl-5-tetrazolyl)-2-pyridin-4-yl-4-thiophen-2-ylpyrimidine

5-(1-Phenyl-5-tetrazolyl)-2-pyridin-4-yl-4-thiophen-2-ylpyrimidine

C20H13N7S (383.0953)


   

3-Pyridin-2-yl-2-(4-quinolin-4-ylphenyl)-1,3-thiazolidin-4-one

3-Pyridin-2-yl-2-(4-quinolin-4-ylphenyl)-1,3-thiazolidin-4-one

C23H17N3OS (383.1092)


   

N-(2,4-dinitrophenyl)-N-sarcosinyl-L-glutamine

N-(2,4-dinitrophenyl)-N-sarcosinyl-L-glutamine

C14H17N5O8 (383.1077)


   
   
   
   

2-[(4E)-4-[[1-(3-ethoxycarbonylphenyl)pyrrol-2-yl]methylidene]-2,5-dioxoimidazolidin-1-yl]acetic acid

2-[(4E)-4-[[1-(3-ethoxycarbonylphenyl)pyrrol-2-yl]methylidene]-2,5-dioxoimidazolidin-1-yl]acetic acid

C19H17N3O6 (383.1117)


   

3-[3-[(E)-(2-acetamido-4-oxo-1,3-thiazol-5-ylidene)methyl]-2,5-dimethylpyrrol-1-yl]benzoic acid

3-[3-[(E)-(2-acetamido-4-oxo-1,3-thiazol-5-ylidene)methyl]-2,5-dimethylpyrrol-1-yl]benzoic acid

C19H17N3O4S (383.094)


   

6-Bromo-3-methyl-9-[2-(6-methylpyridin-3-yl)ethyl]-1,2,3,4-tetrahydro-gamma-carboline

6-Bromo-3-methyl-9-[2-(6-methylpyridin-3-yl)ethyl]-1,2,3,4-tetrahydro-gamma-carboline

C20H22BrN3 (383.0997)


   

atropine methyl bromide

Hyoscyamine methylbromide

C18H26BrNO3 (383.1096)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics Atropine methyl bromide, a muscarinic receptor (mAChR) antagonist, is a quaternary ammonium salt of atropine and a mydriatic for dilation of the pupil during ophthalmic examination. It is introduced for relieving pyloric spasm in infants for its highly polar nature. It penetrates less readily into the central nervous system than atropine[1][2].

   

Succinyladenosine

Succinyladenosine

C14H17N5O8 (383.1077)


An aspartic acid derivative that is L-aspartic acid in which one of the amine hydrogens is substituted by a 9-beta-D-ribofuranosyl-9H-purin-6-yl group.

   
   

(3r)-3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

(3r)-3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

C20H17NO7 (383.1005)


   

8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

C18H22ClNO6 (383.1136)


   

6-[(1s)-6,7-dimethoxy-3-oxo-1h-2-benzofuran-1-yl]-2h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-one

6-[(1s)-6,7-dimethoxy-3-oxo-1h-2-benzofuran-1-yl]-2h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-one

C20H17NO7 (383.1005)


   

(3s)-3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

(3s)-3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

C20H17NO7 (383.1005)


   

(1r,1's,5r,6's,8's)-8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

(1r,1's,5r,6's,8's)-8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

C18H22ClNO6 (383.1136)


   

(1s,1's,5r,6's,8's)-8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

(1s,1's,5r,6's,8's)-8'-chloro-5-hydroxy-2',3',4-trimethoxy-10'-azaspiro[cyclopentane-1,7'-tricyclo[4.3.3.0¹,⁶]dodecane]-2',3-diene-2,4'-dione

C18H22ClNO6 (383.1136)


   

(1r)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-3',5',12'-trioxaspiro[isoquinoline-1,11'-tricyclo[7.4.0.0²,⁶]tridecane]-1'(9'),2'(6'),7'-triene-10',13'-dione

(1r)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-3',5',12'-trioxaspiro[isoquinoline-1,11'-tricyclo[7.4.0.0²,⁶]tridecane]-1'(9'),2'(6'),7'-triene-10',13'-dione

C20H17NO7 (383.1005)


   

3,5,7-trihydroxy-8-[(2r,4s)-5-hydroxy-4-methyl-3,4-dihydro-2h-pyrrol-2-yl]-2-(4-hydroxyphenyl)chromen-4-one

3,5,7-trihydroxy-8-[(2r,4s)-5-hydroxy-4-methyl-3,4-dihydro-2h-pyrrol-2-yl]-2-(4-hydroxyphenyl)chromen-4-one

C20H17NO7 (383.1005)


   

6-(6,7-dimethoxy-3-oxo-1h-2-benzofuran-1-yl)-2h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-one

6-(6,7-dimethoxy-3-oxo-1h-2-benzofuran-1-yl)-2h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-one

C20H17NO7 (383.1005)


   

7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-3',5',12'-trioxaspiro[isoquinoline-1,11'-tricyclo[7.4.0.0²,⁶]tridecane]-1'(9'),2'(6'),7'-triene-10',13'-dione

7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-3',5',12'-trioxaspiro[isoquinoline-1,11'-tricyclo[7.4.0.0²,⁶]tridecane]-1'(9'),2'(6'),7'-triene-10',13'-dione

C20H17NO7 (383.1005)


   

8'-hydroxy-7'-methoxy-6-methyl-7,8-dihydro-2h-spiro[[1,3]dioxolo[4,5-g]isoquinoline-5,3'-[2]benzopyran]-1',4'-dione

8'-hydroxy-7'-methoxy-6-methyl-7,8-dihydro-2h-spiro[[1,3]dioxolo[4,5-g]isoquinoline-5,3'-[2]benzopyran]-1',4'-dione

C20H17NO7 (383.1005)


   

3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

3-hydroxy-7,8-dimethoxy-17,19-dioxa-11-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaene-2,10-dione

C20H17NO7 (383.1005)